Vertex faces pressure from potential U.S. drug pricing reforms and tariffs. Click here to find out why VRTX stock is a Hold.

AI shifts from promise to practice when customization becomes routine. That is a positive sign. When technical teams work with data as it is, measure progress with discipline, and focus on workflows ...

Finance is fast becoming one of the most high-impact areas for AI adoption. From anomaly detection to predictive compliance, today’s AI-powered tools help turn complexity into easily digestible data ...

Our annual healthcare roundtable sizes up the risks and opportunities as public policy shifts. 16 stocks to buy now.

Ratings for Vertex (NASDAQ: VERX) were provided by 7 analysts in the past three months, showcasing a mix of bullish and ...

Vertex's revenue was $2.96 billion in the second quarter of 2025, beating the consensus forecast by $58 million. Click here ...

Ratings for Vertex Pharmaceuticals (NASDAQ: VRTX) were provided by 15 analysts in the past three months, showcasing a mix of ...

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

The FDA granted breakthrough therapy designation to a Vertex Pharmaceuticals kidney disease drug.

Farran Powell is the managing editor of investing at Forbes Advisor. She was previously the assistant managing editor of investing at U.S. News & World Report. Her work has appeared in numerous ...

Dr. JeFreda R. Brown is a financial consultant, Certified Financial Education Instructor, and researcher who has assisted thousands of clients over a more than two-decade career. She is the CEO of ...